The acquisition of Zhejiang Jiang Yuan Tang Biotechnology was agreed back in March with Catalent Pharma Solutions telling in-Pharmatechnologist.com the deal would build upon its existing softgel network in Asia Pacific and complement existing facilities in Japan and Australia.
Now with regulatory requirements met, the firm holds the majority share of Zhejiang Jiang Yuan Tang, based in Haining, and employer of 120.
Speaking in March, Catalent spokesperson Chris Halling told us: “Growing our capabilities in China and Asia more broadly is a key goal for Catalent and has commanded substantial focus from Catalent senior management over the last year and will continue to in the future.”
In April Catalent named Weiyan “Jackson” Zhu as Country General Manager for China.
The firm is also targeting the Asian market with a 31,000 sq ft clinical trials facility under construction in Shanghai.